National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings, 6893-6894 [2021-01445]
Download as PDF
<![CDATA[
jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices
(HHS Reference No. E–003–2014–0–US–
07);
4. International Patent Application
No. PCT/US2015/011433, filed 14
January 2015 (HHS Reference No. E–
003–2014–0–PCT–02);
5. Australia Patent No. 2015206515,
issued 26 March 2020 (HHS Reference
No. E–003–2014–0–AU–03);
6. Canada Patent Application No.
2931005, filed 14 January 2015 (HHS
Reference No. E–003–2014–0–CA–04);
7. European Patent No. 3 094 350 B1,
issued 04 March 2020 (HHS Reference
No. E–003–2014–0–EP–05) and all of its
national validations;
8. European Patent Application No.
19219282.1, filed 14 January 2015 (HHS
Reference No. E–003–2014–0–EP–11);
and
9. any and all other U.S. and ex-U.S.
patents and patent applications
claiming priority to any one of the
foregoing, now or in the future.
The patent and patent application
rights in these inventions have been
assigned and/or exclusively licensed to
the government of the United States of
America.
The prospective exclusive license
territory may be worldwide and the
fields of use may be limited to the
following: The development,
manufacture, distribution, sale and use
of one or more fusion proteins for the
treatment of humans with short stature
associated with one or more genetic
conditions.
These technologies disclose, e.g.,
monoclonal antibodies and antibody
fragments that specifically bind to
matrilin-3, conjugates including these
molecules, and nucleic acid molecules
encoding the antibodies, antigen
binding fragments and conjugates. Also
disclosed are compositions including
the disclosed antibodies, antigen
binding fragments, conjugates, and
nucleic acid molecules. Methods of
treating or inhibiting a cartilage disorder
in a subject, as well as methods of
increasing chondrogenesis in cartilage
tissue are further provided. The
methods can be used, for example, for
treating or inhibiting a growth plate
disorder in a subject, such as a skeletal
dysplasia or short stature.
This Notice is made in accordance
with 35 U.S.C. 209 and 37 CFR 404. The
prospective exclusive license will be
royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published Notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR 404.
VerDate Sep<11>2014
18:31 Jan 22, 2021
Jkt 253001
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: January 11, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2021–01488 Filed 1–22–21; 8:45 am]
6893
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: January 15, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–01443 Filed 1–22–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Environmental
Health Sciences; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel: R21 Mechanism for TimeSensitive Research Opportunities in
Environmental Health Sciences.
Date: February 19, 2021.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Environmental
Health Sciences, Keystone Building, 530
Davis Drive, Durham, NC 27709 (Virtual
Meeting).
Contact Person: Laura A. Thomas, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, National Institute of Environmental
Health Science, Research Triangle Park, NC
27709, 984–287–3328, laura.thomas@
nih.gov.
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; NST–2 Conflict SEP
Additional Applications.
Date: February 18, 2021.
Time: 9:00 a.m. to 10:00 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Delany Torres, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS, Neuroscience Center Building (NSC),
6001 Executive Blvd., Suite 3208, Rockville,
MD 20852, delany.torressalazar@nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; NST–1 Additional
Applications.
Date: March 2, 2021.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\25JAN1.SGM
25JAN1
6894
Federal Register / Vol. 86, No. 14 / Monday, January 25, 2021 / Notices
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: William C. Benzing, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS, NIH, NSC, 6001 Executive Blvd.,
Suite 3204, MSC 9529, Rockville, MD 20852,
(301) 496–0660, benzingw@mail.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; BRAIN Initiative: Research
Resource Grants for Technology Integration
and Dissemination (U24 Clinical Trial Not
Allowed).
Date: March 4, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Bo-Shiun Chen, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH, NSC, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Rockville, MD 20852,
(301) 496–9223, bo-shiun.chen@nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Center Without Walls for
Mechanisms of Neurodegeneration in
Frontotemporal Dementia (FTD) (U54
Clinical Trial Not Allowed).
Date: March 23–24, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Virtual
Meeting).
Contact Person: Bo-Shiun Chen, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH, NSC, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Rockville, MD 20852,
(301) 496–9223, bo-shiun.chen@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: January 15, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–01445 Filed 1–22–21; 8:45 am]
BILLING CODE 4140–01–P
jbell on DSKJLSW7X2PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
18:31 Jan 22, 2021
Jkt 253001
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Phase II
(Topic 166) Leveraging Health IT Solutions to
Combat Opioid Misuse.
Date: February 12, 2021.
Time: 9:00 a.m. to 5:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sheila Pirooznia, Ph.D.,
Scientific Review Officer, Division of
Extramural Review, Scientific Review
Branch, National Institute on Drug Abuse,
NIH, 301 North Stonestreet Avenue, MSC
6021, Bethesda, MD 20892, (301) 496–9350,
sheila.pirooznia@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: January 15, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–01446 Filed 1–22–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; Conference Grant Review.
Date: February 12, 2021.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1076, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Carol Lambert, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1076, Bethesda, MD 20892, 301–435–0814,
lambert@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: January 15, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–01450 Filed 1–22–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Nursing Research;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Nursing Research Initial Review Group.
Date: February 18–19, 2021.
Time: 8:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Nursing
Research, National Institutes of Health, 6701
E:\FR\FM\25JAN1.SGM
25JAN1
]]>Agencies
[Federal Register Volume 86, Number 14 (Monday, January 25, 2021)]
[Notices]
[Pages 6893-6894]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-01445]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; NST-2 Conflict SEP Additional
Applications.
Date: February 18, 2021.
Time: 9:00 a.m. to 10:00 a.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Delany Torres, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Activities, NINDS,
Neuroscience Center Building (NSC), 6001 Executive Blvd., Suite
3208, Rockville, MD 20852, [email protected].
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; NST-1 Additional Applications.
Date: March 2, 2021.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
[[Page 6894]]
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: William C. Benzing, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, NINDS, NIH, NSC, 6001 Executive Blvd., Suite 3204, MSC
9529, Rockville, MD 20852, (301) 496-0660, [email protected].
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; BRAIN Initiative: Research
Resource Grants for Technology Integration and Dissemination (U24
Clinical Trial Not Allowed).
Date: March 4, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Bo-Shiun Chen, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Activities, NINDS/
NIH, NSC, 6001 Executive Blvd., Suite 3208, MSC 9529, Rockville, MD
20852, (301) 496-9223, [email protected].
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Center Without Walls for
Mechanisms of Neurodegeneration in Frontotemporal Dementia (FTD)
(U54 Clinical Trial Not Allowed).
Date: March 23-24, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).
Contact Person: Bo-Shiun Chen, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of Extramural Activities, NINDS/
NIH, NSC, 6001 Executive Blvd., Suite 3208, MSC 9529, Rockville, MD
20852, (301) 496-9223, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research Related to Neurological Disorders; 93.854,
Biological Basis Research in the Neurosciences, National Institutes
of Health, HHS)
Dated: January 15, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-01445 Filed 1-22-21; 8:45 am]
BILLING CODE 4140-01-P
